Compare ATEC & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATEC | SNDX |
|---|---|---|
| Founded | 1990 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2006 | 2014 |
| Metric | ATEC | SNDX |
|---|---|---|
| Price | $10.72 | $16.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 12 |
| Target Price | $15.79 | ★ $37.55 |
| AVG Volume (30 Days) | ★ 2.3M | 1.6M |
| Earning Date | 10-29-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.04 | 11.56 |
| EPS | ★ N/A | N/A |
| Revenue | $101,739,000.00 | ★ $172,352,000.00 |
| Revenue This Year | $15.43 | $82.71 |
| Revenue Next Year | $15.24 | $45.79 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 627.84 |
| 52 Week Low | $6.82 | $13.00 |
| 52 Week High | $23.29 | $25.59 |
| Indicator | ATEC | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 58.70 | 36.00 |
| Support Level | $10.61 | N/A |
| Resistance Level | $11.03 | $18.75 |
| Average True Range (ATR) | 0.39 | 0.75 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 80.71 | 19.22 |
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.